BlossomHill Therapeutics (BLSM) Registration filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company focused on small molecule medicines for cancer treatment.

• Lead programs target EGFR-mutant NSCLC, relapsed/refractory AML, HR-MDS, and KRAS-mutant solid tumors.

• Pipeline includes two clinical-stage and one preclinical-stage product candidates, all wholly owned.

• Founded in 2020, led by a team with a track record in oncology drug development.

Financial performance and metrics

• Net losses of $30.7M in 2024 and $60.6M in 2025; accumulated deficit of $156.0M as of March 31, 2026.

• Cash and cash equivalents of $116.0M as of March 31, 2026.

• Research and development expenses increased from $31.8M in 2024 to $56.1M in 2025.

• No revenue from product sales to date; expects continued operating losses for the foreseeable future.

Use of proceeds and capital allocation

• Proceeds will fund clinical development of BH-30643 (EGFR-mutant NSCLC), BH-30236 (AML, HR-MDS), and BH-501284 (pan-KRAS solid tumors).

• Remaining funds allocated to R&D, capital expenditures, working capital, and general corporate purposes.

• Proceeds, together with existing cash, expected to fund operations into the future, but not through commercialization.